Liquidseq Comprehensive Panel [275]
About Liquidseq Comprehensive Panel [275]
| Field | Value |
|---|---|
| Also Known As | ctDNA Comprehensive Cancer Panel, Comprehensive Genomic Profiling (CGP) Liquid Biopsy, 275-Gene Liquid Biopsy Panel, Circulating Tumour DNA Comprehensive Panel |
| Sample Type | Peripheral blood (plasma) |
| Fasting Required | No fasting required |
| Report Time | 30 days |
| Recommended For | Adults with solid tumours; males and females |
| Price | Starting at ₹1,62,000 |
What Is a Liquidseq Comprehensive Panel [275]?
The Liquidseq comprehensive panel [275] test is an advanced blood-based cancer genomic test that analyses circulating tumour DNA (ctDNA), small fragments of DNA shed by tumour cells into the bloodstream. Using next-generation sequencing (NGS), it examines 275 cancer-related genes to identify mutations that may guide treatment decisions. It is also known as the 275-gene liquid biopsy panel. A single blood sample is all that is required.
What Does a Liquidseq Comprehensive Panel [275] Measure?
This test examines a wide range of genetic changes across 275 cancer-related genes. The key parameters it evaluates are listed below.
| Parameter | What It Means |
|---|---|
| Single Nucleotide Variants (SNVs) | Single-letter changes in the DNA code that may drive cancer growth |
| Insertions and Deletions (Indels) | Small additions or removals of DNA letters that can alter gene function |
| Gene Amplifications | Extra copies of certain genes that may fuel tumour growth |
| Gene Fusions/Translocations | Abnormal joining of two genes that can produce cancer-promoting proteins |
| Tumour Mutational Burden (TMB) | Total number of mutations in tumour DNA; may predict response to immunotherapy |
| Microsatellite Instability (MSI) | Instability in certain DNA sequences, suggesting possible DNA repair defects |
Why Is a Liquidseq Comprehensive Panel [275] Done?
Doctors order this test to understand the genetic profile of a tumour, to guide treatment choices, and to track disease progression. It has clinical applications in lung, breast, colorectal, pancreatic, and prostate cancers, among others.
Common Symptoms That May Require This Test
A doctor may recommend the Liquidseq comprehensive panel [275] test if a patient presents with any of the following symptoms.
- Unexplained weight loss
- Persistent fatigue without a clear cause
- Recurrent infections
- Abnormal bleeding
- Lumps or masses discovered during examination
- Ongoing, unexplained pain
- Shortness of breath
Conditions This Test Can Help Detect
The Liquidseq comprehensive panel [275] test can assist in identifying or characterising the following.
- Selection of targeted cancer therapies based on specific mutations (such as EGFR, ALK, BRAF, KRAS, and BRCA mutations)
- Detection of drug resistance mutations during ongoing treatment (for example, EGFR-T790M in lung cancer patients on targeted therapy)
- Monitoring of treatment response and detection of early relapse or minimal residual disease (MRD)
- Identification of hereditary cancer risk through germline mutation detection
- Early cancer detection in patients where tissue biopsy is not feasible
Liquidseq Comprehensive Panel [275] for Chronic Disease Monitoring
Cancer patients on targeted therapy or immunotherapy may have this test repeated over time. Compared to tissue-based testing, ctDNA testing captures genetic changes as they evolve and allows repeated assessments without invasive procedures. This makes it useful for tracking treatment response, detecting resistance mutations, and identifying early signs of disease recurrence.
How to Prepare and What to Expect
No complicated preparation is needed for this test. The steps below will help you arrive ready for a smooth sample collection.
Do You Need to Fast?
No, fasting is not required before this test. You may eat and drink normally before your appointment. If you have been prescribed additional tests alongside this one, check with your doctor whether any of those require fasting.
Practical Tips Before Your Test
The following tips will help ensure your sample is collected under the best possible conditions.
- Inform your doctor about all medications you are currently taking, especially blood thinners, immunosuppressants, or chemotherapy drugs
- Stay well hydrated before the blood draw
- Discuss the timing of the test with your oncologist if you are currently undergoing active treatment, as recent chemotherapy may affect results
- Bring a detailed clinical history including your symptoms, previous test results, and family history, as this is required for the test
- No special dietary restrictions are necessary before the test
Step-by-Step Procedure
The Liquidseq comprehensive panel [275] test involves the following steps:
- You will be seated comfortably, and a trained phlebotomist will clean a vein in your arm with an antiseptic.
- A blood sample of approximately 10 ml will be drawn into a specialised Streck tube, which is designed to preserve cell-free DNA (cfDNA) in the sample.
- The tube is labelled with your details, and your clinical history is noted, as this is required for accurate interpretation.
- The sample is refrigerated (between 2°C and 8°C) and dispatched to the laboratory promptly to prevent degradation of DNA.
- In the laboratory, plasma is separated from the blood, and ctDNA is extracted from it.
- The extracted DNA is then analysed using next-generation sequencing (NGS) technology across all 275 targeted genes.
Factors That Can Affect Accuracy
Several factors can influence the reliability of the results. These include the following.
- Tumour stage and size: Advanced or larger tumours shed more ctDNA, improving detection
- Low tumour fraction (below 1%) may lead to a false-negative result
- Recent chemotherapy may temporarily reduce ctDNA levels in the blood
- Time between sample collection and processing: Delays can degrade the sample
- Storage temperature and collection tube quality
- Clonal haematopoiesis, which refers to age-related mutations in blood cells that can act as a confounding factor
Understanding Your Liquidseq Comprehensive Panel [275] Results
Results from this test are qualitative rather than numerical. A qualified oncologist or medical geneticist should always review your report in the context of your clinical history, imaging, and prior treatment.
| Result Category | What It May Indicate |
|---|---|
| Pathogenic or Likely Pathogenic Variants Detected | Clinically significant mutations found; may guide targeted therapy selection |
| Variants of Uncertain Significance (VUS) | Genetic changes have been identified, but clinical significance is currently unclear |
| No Variants Detected | No actionable mutations found in the tested genes |
| Tumour Fraction above 1% | Higher confidence in the accuracy of results |
Variants identified in this panel are classified using a tiered system. Tier 1 variants carry strong clinical significance, while Tier 2 variants carry potential clinical significance.
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain situations can affect how results are interpreted. Your oncologist will account for these when reviewing your report.
- Clonal haematopoiesis (age-related mutations in blood cells) can mimic tumour-derived mutations and requires careful technical analysis to distinguish true tumour variants.
- Early-stage cancers may not shed enough ctDNA for reliable detection, which can result in a false-negative outcome; tissue biopsy may be recommended to confirm such results.
- Recent chemotherapy may reduce circulating ctDNA levels and temporarily affect the sensitivity of the test.
How to Maintain Healthy Levels
This test is used in an oncology context, so the following tips are framed as general guidance for patients undergoing monitoring.
- Follow your oncologist's schedule for repeat testing and medical check-ups.
- If hereditary mutations are identified in your results, consider speaking with a genetic counsellor to understand the implications for you and your family.
- Keep a record of all previous test results so your doctor can track changes over time.
Lupin Diagnostics Liquidseq Comprehensive Panel [275] Price
The Liquidseq comprehensive panel [275] test starts at ₹1,62,000 at Lupin Diagnostics. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this test due to the specialised sample handling required.
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 162000 |
| Pune | 162000 |
| Bangalore | 162000 |
| Chennai | 162000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to schedule your Liquidseq comprehensive panel [275] test online booking.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
The Liquidseq comprehensive panel [275] test is a liquid biopsy test that uses next-generation sequencing to analyse circulating tumour DNA from a blood sample. It examines 275 cancer-related genes to identify mutations, guide treatment decisions, and monitor disease progression. It is designed for patients with solid tumours.
A traditional tissue biopsy involves removing a piece of tissue from the tumour, which can be invasive and is not always feasible. This test requires only a blood draw, making it less invasive and easier to repeat over time. It also captures genetic information from multiple tumour sites, reducing the risk of sampling bias.
This test is typically recommended for adults with solid tumours, particularly those with advanced or metastatic cancer. It is also suitable for patients who cannot undergo tissue biopsy or those who need ongoing monitoring for treatment response or resistance mutations. Your oncologist will advise whether this test is right for you.
The report is delivered within 30 days. This accounts for the time needed for NGS analysis, variant classification, and clinical report preparation. Your doctor will walk you through the findings once the report is available.
A negative result may reflect the true genetic profile of the tumour, meaning no actionable mutations are present. However, it may also indicate that insufficient ctDNA was shed into the blood, particularly in early-stage cancers. Your oncologist may recommend a tissue biopsy to confirm a negative liquid biopsy result.
The procedure involves a standard blood draw at a Lupin Diagnostics centre. Blood is collected into a specialised tube, refrigerated, and sent to the laboratory. There is no surgical procedure involved, and the experience is similar to any routine blood test.
Liquid biopsy panels show promise for detecting cancer-associated mutations in the blood. However, early-stage tumours tend to shed very little ctDNA, which can limit detection sensitivity at that stage. This test is most reliably used for guiding treatment in known cancer cases and for monitoring disease over time.
Liquidseq Comprehensive Panel [275]
